Aptalis

This afternoon, Forest Laboratories (NYSE: FRX) said that it would buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion in cash, and rights. This deal also includes milestone payments to access Furiex's promising treatment for irritable bowel syndrome (IBS). “The acquisition of...